<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; CRL</title>
	<atom:link href="http://www.stockbloghub.com/tag/crl/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Tue, 22 May 2012 18:53:06 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ITMN) InterMune Fourth Quarter Esbriet Sales Snapshot</title>
		<link>http://www.stockbloghub.com/2012/01/13/itmn-intermune-fourth-quarter-esbriet-sales-snapshot/89940</link>
		<comments>http://www.stockbloghub.com/2012/01/13/itmn-intermune-fourth-quarter-esbriet-sales-snapshot/89940#comments</comments>
		<pubDate>Fri, 13 Jan 2012 20:59:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[InterMune Inc]]></category>
		<category><![CDATA[IPF]]></category>
		<category><![CDATA[ITMN]]></category>
		<category><![CDATA[NPP]]></category>
		<category><![CDATA[Nuveen Performance Plus Municipal Fund Inc]]></category>
		<category><![CDATA[SPDR S&P International Financial Sector]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89940</guid>
		<description><![CDATA[InterMune, Inc. (ITMN) recently reported preliminary fourth quarter revenue for its potential blockbuster drug Esbriet. Esbriet is approved in the European Union (EU) for the treatment of mild-to-moderate idiopathic pulmonary fibrosis (IPF). The drug has been launched first in Germany in September 2011. InterMune also announced updated data from the drug’s RECAP study. Preliminary Esbriet Update InterMune reported Esbriet revenue of $2.8 million since launch in September 2011, of which $2.7 million was generated in Germany. Management announced that 1,022 new patients started Esbriet therapy across EU at the end of 2011. Of these, 612 patients have been given Esbriet in Germany and 410 patients have enrolled in the named patient program (NPP) outside Germany. Under the NPP program qualified physicians can make Esbriet available to IPF patients in EU ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/13/itmn-intermune-fourth-quarter-esbriet-sales-snapshot/89940/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PPDI) Pharmaceutical Product Development Shareholders Nod to Merger</title>
		<link>http://www.stockbloghub.com/2011/12/06/ppdi-pharmaceutical-product-development-shareholders-nod-to-merger/87968</link>
		<comments>http://www.stockbloghub.com/2011/12/06/ppdi-pharmaceutical-product-development-shareholders-nod-to-merger/87968#comments</comments>
		<pubDate>Tue, 06 Dec 2011 19:34:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[Claymore-Zacks Country Rotation]]></category>
		<category><![CDATA[Credit Suisse Group]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[CRO]]></category>
		<category><![CDATA[CS]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[Pharmaceutical Product Development Inc]]></category>
		<category><![CDATA[PPDI]]></category>
		<category><![CDATA[UBS]]></category>
		<category><![CDATA[UBS AG]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87968</guid>
		<description><![CDATA[Pharmaceutical drug research company Pharmaceutical Product Development, Inc. (PPDI) recently announced that its shareholders have approved the merger with privately held firms The Carlyle Group and Hellman &#38; Friedman. The merger was announced in October 2011. PPD shareholders have been offered a cash consideration of $33.25 per share. The total purchase consideration comes to $3.9 billion in cash. The merger is now subject to certain closing conditions and is expected to close before the end of 2011, following which PPD will become a private company and will no longer trade on NASDAQ. Four banks have committed to finance the deal. These include Credit Suisse (CS), JP Morgan (JPM), Goldman Sachs (GS) and UBS (UBS). Because of the buyout, PPD did not hold a conference call to discuss the third quarter ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/06/ppdi-pharmaceutical-product-development-shareholders-nod-to-merger/87968/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THRX) Theravance Third Quarter Loss Deteriorates</title>
		<link>http://www.stockbloghub.com/2011/11/02/thrx-theravance-third-quarter-loss-deteriorates/86313</link>
		<comments>http://www.stockbloghub.com/2011/11/02/thrx-theravance-third-quarter-loss-deteriorates/86313#comments</comments>
		<pubDate>Wed, 02 Nov 2011 21:01:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[FF]]></category>
		<category><![CDATA[First Opportunity Fund Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ICS]]></category>
		<category><![CDATA[Morgan Stanley Insured California Municipal Securi]]></category>
		<category><![CDATA[Neenah Paper Inc.]]></category>
		<category><![CDATA[NP]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86313</guid>
		<description><![CDATA[Theravance Inc.’s (THRX) third quarter 2011 loss per share of 37 cents was wider than the Zacks Consensus loss Estimate of 33 cents as well as the year-ago loss of 29 cents per share. The wider loss was attributable to a lukewarm top-line performance as well as increased research and development (R&#38;D) expenses. Revenue at Theravance though up 21.3% over the prior year to $6.4 million was below the Zacks Consensus Estimate of $7 million. The Quarter in Detail Revenues for the quarter primarily consisted of the amortization of deferred revenues received under the company’s collaborations with Astellas Pharma and GlaxoSmithKline plc (GSK). Theravance earned a royalty of $0.8 million on Vibativ sales from Astellas Pharma on net sales of $4.5 million. Vibativ, Theravance’s only commercialized drug, is an injectable ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/02/thrx-theravance-third-quarter-loss-deteriorates/86313/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PPDI) Pharmaceutical Product Development to Go Private</title>
		<link>http://www.stockbloghub.com/2011/10/11/ppdi-pharmaceutical-product-development-to-go-private/84787</link>
		<comments>http://www.stockbloghub.com/2011/10/11/ppdi-pharmaceutical-product-development-to-go-private/84787#comments</comments>
		<pubDate>Tue, 11 Oct 2011 15:39:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[Claymore-Zacks Country Rotation]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[CRO]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[Pharmaceutical Product Development Inc]]></category>
		<category><![CDATA[PPDI]]></category>
		<category><![CDATA[UBS]]></category>
		<category><![CDATA[UBS AG]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=84787</guid>
		<description><![CDATA[Pharmaceutical drug research company Pharmaceutical Product Development, Inc. (PPDI) recently announced that it has entered into an agreement to be acquired by privately held The Carlyle Group and Hellman &#38; Friedman for $3.9 billion in cash. PPD shareholders have been offered a cash consideration of $33.25 per share, a premium of 29.6% over the stock’s closing price on September 30. The transaction has won unanimous approval of PPD’s board while shareholder approval is awaited. The transaction is expected to close in the fourth quarter of 2011, following which PPD will become a private company and will no longer trade on NASDAQ. Four banks have committed to finance the deal. These include Credit Suisse, JP Morgan (JPM), Goldman Sachs (GS) and UBS (UBS). PPD has 30 days to solicit superior proposals ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/11/ppdi-pharmaceutical-product-development-to-go-private/84787/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OREX) Orexigen Therapeutics Lifeline for Contrave</title>
		<link>http://www.stockbloghub.com/2011/09/24/orex-orexigen-therapeutics-lifeline-for-contrave/83937</link>
		<comments>http://www.stockbloghub.com/2011/09/24/orex-orexigen-therapeutics-lifeline-for-contrave/83937#comments</comments>
		<pubDate>Sat, 24 Sep 2011 19:00:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Arena Pharmaceuticals Inc.]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[Orexigen Therapeutics Inc.]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83937</guid>
		<description><![CDATA[Orexigen Therapeutics, Inc.&#8216;s (OREX) shares climbed significantly following a meeting with the US Food and Drug Administration&#8217;s (FDA) office of new drugs (OND) regarding the development path for its obesity candidate Contrave. Following the OND’s decision, Orexigen decided to resume the development of Contrave. Orexigen is looking to gain approval for Contrave for the treatment of obesity, including weight loss and maintenance of weight loss. The company has a collaboration agreement with Takeda for the development and commercialization of Contrave in the US, Canada and Mexico. Story so far…. In January 2011, Orexigen received a complete response letter (CRL) from the FDA for Contrave. The FDA  expressed concerns regarding the long-term cardiovascular safety profile of Contrave and asked Orexigen to conduct an additional study. The FDA requested a randomized, double-blind, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/24/orex-orexigen-therapeutics-lifeline-for-contrave/83937/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PPDI) Pharmaceutical Product Development Hires New CEO</title>
		<link>http://www.stockbloghub.com/2011/09/24/ppdi-pharmaceutical-product-development-hires-new-ceo/84028</link>
		<comments>http://www.stockbloghub.com/2011/09/24/ppdi-pharmaceutical-product-development-hires-new-ceo/84028#comments</comments>
		<pubDate>Sat, 24 Sep 2011 18:54:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[Claymore-Zacks Country Rotation]]></category>
		<category><![CDATA[CNOOC Limited]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[CRO]]></category>
		<category><![CDATA[Pharmaceutical Product Development Inc]]></category>
		<category><![CDATA[PPDI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=84028</guid>
		<description><![CDATA[Pharmaceutical Product Development, Inc. (PPDI) recently announced the appointment of Mr. Raymond Hill as its new Chief Executive Officer (CEO) and also a member of the Board of Directors effective from September 16. Raymond Hill was the president of IMS Consulting Group at IMS Health Inc. Prior to joining IMS Health, Mr. Hill served as a senior vice president for Acumen Sciences Limited. PPD also recently announced expansion of its clinical microbiology laboratory globally to strengthen its laboratory services in infectious diseases to meet growing client demand. With the expansion, PPD can offer a full range of microbiology testing services such as bacteriology, mycobacteriology and testing of microbioterrorism pathogens. Our Recommendation We currently have a Hold recommendation on PPD. The company retains a Zacks #3 Rank, which translates into a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/24/ppdi-pharmaceutical-product-development-hires-new-ceo/84028/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HGSI) Human Genome Sciences Analyst Maintains Neutral Recommendation</title>
		<link>http://www.stockbloghub.com/2011/08/22/hgsi-human-genome-sciences-analyst-maintains-neutral-recommendation/81747</link>
		<comments>http://www.stockbloghub.com/2011/08/22/hgsi-human-genome-sciences-analyst-maintains-neutral-recommendation/81747#comments</comments>
		<pubDate>Mon, 22 Aug 2011 14:47:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sara Lee Corporation]]></category>
		<category><![CDATA[SLE]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81747</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Human Genome Sciences Inc. (HGSI) with a target price of $16.00. Human Genome, founded in 1992 and based in Rockville, Maryland, is a biopharmaceutical company. The US launch of Benlysta earlier in the year for treating patients suffering from systemic lupus erythematosus (SLE) is a huge positive for Human Genome. The subsequent approvals of the drug in the European Union (EU) and Canada are also encouraging. The drug, which has blockbuster potential, has been co-developed with GlaxoSmithKline (GSK). Benlysta is the first new lupus drug to be cleared in more than 50 years. Lupus is a potentially fatal autoimmune disease that is extremely difficult to treat. We believe that the approval of this potentially blockbuster candidate will drive Human Genome to profitability. Benlysta ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/22/hgsi-human-genome-sciences-analyst-maintains-neutral-recommendation/81747/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics Quarterly Earnings Lag &#8211; Company Pares Loss</title>
		<link>http://www.stockbloghub.com/2011/08/03/ctic-cell-therapeutics-quarterly-earnings-lag-company-pares-loss/80335</link>
		<comments>http://www.stockbloghub.com/2011/08/03/ctic-cell-therapeutics-quarterly-earnings-lag-company-pares-loss/80335#comments</comments>
		<pubDate>Wed, 03 Aug 2011 15:45:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[CTIC]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[MDS]]></category>
		<category><![CDATA[Midas Inc.]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80335</guid>
		<description><![CDATA[Cell Therapeutics (CTIC) suffered a net loss of 14 cents per share in the second quarter of 2011, compared with a net loss of 46 cents (excluding special items) per share in the year-ago quarter. The narrower loss per share in the reported quarter was due to lower operating expenses and lower deemed dividend paid to preferred shareholders. The Zacks Consensus Estimate for the reported quarter was a loss of 12 cents per share. Cell Therapeutics did not generate any revenue during the reported quarter versus $0.029 million in the second quarter of 2010. Total operating expense in the quarter declined 15% to $16.9 million. Pipeline Update In June this year, Cell Therapeutics met with the Division of Oncology Drug Products (the DODP) of the US Food and Drug Administration ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/03/ctic-cell-therapeutics-quarterly-earnings-lag-company-pares-loss/80335/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Pharmaceuticals Loss Narrows on Lower Costs</title>
		<link>http://www.stockbloghub.com/2011/07/27/amln-amylin-pharmaceuticals-loss-narrows-on-lower-costs/80027</link>
		<comments>http://www.stockbloghub.com/2011/07/27/amln-amylin-pharmaceuticals-loss-narrows-on-lower-costs/80027#comments</comments>
		<pubDate>Thu, 28 Jul 2011 04:23:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CMC]]></category>
		<category><![CDATA[Commercial Metals Company]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80027</guid>
		<description><![CDATA[Amylin Pharmaceuticals (AMLN) reported a net loss of 21 cents per share in the second quarter of 2011, a penny wider than the Zacks Consensus Estimate but well below the year-ago loss of 28 cents. Despite a decline in revenues, year-over-year loss declined due to lower expenses. Second quarter revenues declined 3.8% to $158.1 million. Revenues, however, exceeded the Zacks Consensus Estimate of $156 million. Quarterly Details Total revenues for the quarter declined mainly due to lower net product sales. Quarterly revenues consisted of $154.8 million in product sales (down 4.8%) and $3.3 million in collaborative revenues, which consist of the amortization of upfront fees received under the company&#8217;s collaboration agreements with Eli Lilly (LLY) and Takeda. Product revenues comprised $129 million in sales of Byetta (exenatide) and $25.8 million ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/27/amln-amylin-pharmaceuticals-loss-narrows-on-lower-costs/80027/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENDP) Endo Pharmaceuticals Announces FDA Action Date</title>
		<link>http://www.stockbloghub.com/2011/06/27/endp-endo-pharmaceuticals-announces-fda-action-date/77598</link>
		<comments>http://www.stockbloghub.com/2011/06/27/endp-endo-pharmaceuticals-announces-fda-action-date/77598#comments</comments>
		<pubDate>Mon, 27 Jun 2011 18:46:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77598</guid>
		<description><![CDATA[Endo Pharmaceuticals (ENDP) recently announced that the US Food and Drug Administration (FDA) has issued a new action date for the new formulation of painkiller Opana ER. The FDA stated that it will review Endo Pharma’s response to the agency’s complete response letter (CRL) by December 13, 2011. The new formulation of Opana ER is designed to resist attempts of crushing, breaking, pulverizing or making a powder of the product. The candidate aims to bring relief to patients suffering from moderate-to-severe pain and in need of continuous opioid treatment for an extended period of time. CRL Issued in January 2011 On January 7, 2011, Endo Pharma announced that the FDA had issued a CRL for the painkiller. Even though the US regulatory body declined to approve the new formulation of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/27/endp-endo-pharmaceuticals-announces-fda-action-date/77598/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics Set to Resubmit Pixantrone NDA</title>
		<link>http://www.stockbloghub.com/2011/06/17/ctic-cell-therapeutics-set-to-resubmit-pixantrone-nda/76603</link>
		<comments>http://www.stockbloghub.com/2011/06/17/ctic-cell-therapeutics-set-to-resubmit-pixantrone-nda/76603#comments</comments>
		<pubDate>Fri, 17 Jun 2011 14:50:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[CTIC]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76603</guid>
		<description><![CDATA[Cell Therapeutics (CTIC) recently met with the Division of Oncology Drug Products (the DODP) of the US Food and Drug Administration (FDA) and received guidance for resubmission of the new drug application (NDA) for its lead pipeline candidate pixantrone. Pixantrone has been developed for the treatment of relapsed or refractory aggressive non-Hodgkin’s lymphoma (NHL) in patients who have not responded to other treatment options. The company is also looking for accelerated approval of the NDA based on data from the PIX301 study. The meeting follows the early May decision of the Office of New Drugs (OND) of the FDA allowing the company to re-submit the NDA for pixantrone for review without the need for an additional trial. The OND recommended Cell Therapeutics to conduct an additional independent radiologic review utilizing ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/17/ctic-cell-therapeutics-set-to-resubmit-pixantrone-nda/76603/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THRX) Theravance Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-on-shares-2/76322</link>
		<comments>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-on-shares-2/76322#comments</comments>
		<pubDate>Wed, 15 Jun 2011 03:24:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HAP]]></category>
		<category><![CDATA[Market Vectors RVE Hard Assets Prod ETF]]></category>
		<category><![CDATA[Neenah Paper Inc.]]></category>
		<category><![CDATA[NP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76322</guid>
		<description><![CDATA[We have maintained our Neutral recommendation on Theravance, Inc. (THRX) with a target price of $24.00 per share following the announcement of first quarter 2011 financial results. Theravance’s first quarter 2011 loss per share of 28 cents was in line with the Zacks Consensus Estimate, but narrower than the year-ago loss of 35 cents per share. Revenues at Theravance increased 10% year over year to $6.3 million. An increase in royalty revenues from Vibativ sales in the reported quarter was attributable for both the jump in revenues and the narrower year-over-year loss per share. However, total revenue was below the Zacks Consensus Revenue Estimate of $7 million. Theravance has active collaborations with GlaxoSmithKline (GSK) for the Relovair, LAMA/LABA (also called 719/VI) and MABA programs. The Relovair program holds the biggest ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-on-shares-2/76322/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENDP) Endo Pharmaceuticals Evenly Poised</title>
		<link>http://www.stockbloghub.com/2011/05/30/endp-endo-pharmaceuticals-evenly-poised/74362</link>
		<comments>http://www.stockbloghub.com/2011/05/30/endp-endo-pharmaceuticals-evenly-poised/74362#comments</comments>
		<pubDate>Mon, 30 May 2011 15:24:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[American Medical Systems Holdings Inc]]></category>
		<category><![CDATA[AMMD]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=74362</guid>
		<description><![CDATA[We are maintaining our Neutral stance on Endo Pharmaceuticals (ENDP) with a target price of $44.00. Headquartered in Chadds Ford, Pennsylvania and founded in 1997, Endo Pharma is a specialty healthcare solutions company. The company, which operates in the US, reports results through three segments: Branded Pharmaceuticals, Generics and Devices and Services. Endo Pharma offers more than 175 products in the areas of pain management, urology and oncology. In April 2011, Endo Pharma reported its first quarter 2011 results. First quarter adjusted earnings of $1.00 per share were in line with the Zacks Consensus Estimate but $0.26 above the year ago figure. The year-over-year rise in earnings was attributable to the higher revenues reported in the first quarter of 2011. We note that Endo Pharma is on an acquisition spree ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/30/endp-endo-pharmaceuticals-evenly-poised/74362/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRX) Valeant Pharmaceuticals Beats Earnings Estimates on Revenues</title>
		<link>http://www.stockbloghub.com/2011/05/18/vrx-valeant-pharmaceuticals-beats-earnings-estimates-on-revenues/73944</link>
		<comments>http://www.stockbloghub.com/2011/05/18/vrx-valeant-pharmaceuticals-beats-earnings-estimates-on-revenues/73944#comments</comments>
		<pubDate>Wed, 18 May 2011 15:22:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73944</guid>
		<description><![CDATA[Valeant Pharmaceuticals International‘s (VRX) first quarter 2011 earnings of 49 cents per share (excluding special items but including stock-based compensation expense) missed the Zacks Consensus Estimate by 2 cents and the year-ago earnings by 10 cents per share. Revenues for the quarter increased to $565 million, well above the Zacks Consensus Estimate of $517 million and the prior-year quarter’s revenue of $219.6 million. However, revenue included a one-time alliance and royalty revenue of $36 million related to the March 2011 out-licensing of product rights to Cloderm cream, a mid-potency steroid to Dr. Reddy&#8217;s Laboratories (RDY). Excluding the one-time payment, revenue was $529 million, which was still above both the Zacks Consensus Estimate and the prior-year revenue. Organically (excluding the impact of one-time revenues, acquisitions and foreign exchange), revenues grew 7% ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/18/vrx-valeant-pharmaceuticals-beats-earnings-estimates-on-revenues/73944/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CRL) Charles River Laboratories International Beats The Street</title>
		<link>http://www.stockbloghub.com/2011/05/09/crl-charles-river-laboratories-international-beats-the-street/73633</link>
		<comments>http://www.stockbloghub.com/2011/05/09/crl-charles-river-laboratories-international-beats-the-street/73633#comments</comments>
		<pubDate>Mon, 09 May 2011 21:35:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73633</guid>
		<description><![CDATA[Charles River Laboratories International Inc. (CRL) reported first quarter 2011 earnings (excluding special items) of 61 cents per share, above the Zacks Consensus Estimate of 55 cents and year-ago earnings of 45 cents. Quarterly revenue of $285.8 million was, however, down 2.2% from the prior-year period (down 3.0% excluding positive impact of foreign exchange) due to a decline in Preclinical Services (PCS) segment revenues. Earnings were boosted by lower taxes, share repurchases and improved operating margins, which offset the decline in revenue. Revenue was, however, above the Zacks Consensus Estimate of $279 million and also up approximately 1.5% from the sequentially prior quarter. The Quarter in Detail The company operates through two segments &#8211; Research Models and Services (RMS) and Preclinical Services (PCS). Revenue from the RMS segment was $173.4 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/09/crl-charles-river-laboratories-international-beats-the-street/73633/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PPDI) Pharmaceutical Product Development Misses Estimates by a Penny</title>
		<link>http://www.stockbloghub.com/2011/05/03/ppdi-pharmaceutical-product-development-misses-estimates-by-a-penny/72677</link>
		<comments>http://www.stockbloghub.com/2011/05/03/ppdi-pharmaceutical-product-development-misses-estimates-by-a-penny/72677#comments</comments>
		<pubDate>Tue, 03 May 2011 19:09:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[Claymore-Zacks Country Rotation]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[CRO]]></category>
		<category><![CDATA[Pharmaceutical Product Development Inc]]></category>
		<category><![CDATA[PPDI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=72677</guid>
		<description><![CDATA[Pharmaceutical Product Development, Inc. (PPDI) reported first quarter 2011 earnings of 32 cents per share, above the year-ago earnings of 14 cents per share. Earnings growth was driven by higher revenue, improved gross margins and reduced SG&#38;A expenses. Earnings however came a penny below the Zacks Consensus Estimate of 33 cents. Quarterly revenue of $383.2 million was up 10.5% over the prior-year period and also ahead of the Zacks Consensus Estimate of $360 million. Revenue growth was driven by strong performance of the Clinical Development segment. The Quarter in Detail The company operates through two segments &#8211; Clinical Development Services and Laboratory Services Clinical Development Services: The segment includes global phase II-IV clinical trial management services.  In the first quarter, the segment revenue was $279.7 million, up 12.2% over the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/03/ppdi-pharmaceutical-product-development-misses-estimates-by-a-penny/72677/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CRL) Charles River Laboratories Earnings Beat The Street</title>
		<link>http://www.stockbloghub.com/2011/02/11/crl-charles-river-laboratories-earnings-beat-the-street/66743</link>
		<comments>http://www.stockbloghub.com/2011/02/11/crl-charles-river-laboratories-earnings-beat-the-street/66743#comments</comments>
		<pubDate>Fri, 11 Feb 2011 15:41:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[MetroPCS Communications Inc.]]></category>
		<category><![CDATA[PCS]]></category>
		<category><![CDATA[Pharmaceutical Product Development Inc]]></category>
		<category><![CDATA[PPDI]]></category>
		<category><![CDATA[RMS]]></category>
		<category><![CDATA[Rydex Inverse 2x S&P MidCap 400]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=66743</guid>
		<description><![CDATA[Charles River Laboratories International Inc. (CRL) reported fourth quarter 2010 earnings (excluding special items) of 60 cents per share, much above the Zacks Consensus Estimate and year-ago earnings of 49 cents. Quarterly revenue of $281.7 million was, however, down 2.9% from the prior year period due to a decline in Preclinical Services (PCS) segment revenues. Earnings were boosted by lower taxes, share repurchases and cost control, which offset the decline in revenue. Revenue was, however, above the Zacks Consensus Estimate of $272 million. For full year 2010, Charles River reported earnings of $1.99 per share, above the Zacks Consensus Estimate of $1.88 and the guidance range of $1.88-$1.93. Earnings, however, lagged the year-ago figure of $2.35 per share. Revenues, which were in line with the Zacks Consensus Estimate, declined 3.3% ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/02/11/crl-charles-river-laboratories-earnings-beat-the-street/66743/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OREX) Orexigen Therapeutics Gets Severe Setback from US Food and Drug Administration</title>
		<link>http://www.stockbloghub.com/2011/02/03/orex-orexigen-therapeutics-gets-severe-setback-from-us-food-and-drug-administration/66226</link>
		<comments>http://www.stockbloghub.com/2011/02/03/orex-orexigen-therapeutics-gets-severe-setback-from-us-food-and-drug-administration/66226#comments</comments>
		<pubDate>Thu, 03 Feb 2011 17:21:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Arena Pharmaceuticals Inc.]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[COR]]></category>
		<category><![CDATA[Cortex Pharmaceuticals Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[Orexigen Therapeutics Inc.]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=66226</guid>
		<description><![CDATA[Orexigen Therapeutics Inc. (OREX) was dealt a severe blow by the US Food and Drug Administration (FDA) when the regulatory body declined to approve its obesity drug, Contrave in the present form and issued a complete response letter (CRL). Contrave, which aimed at addressing the physiological and behavioral causes of obesity, has been co-developed with Japan’s Takeda. While issuing the CRL, dated January 31, 2011, the FDA stated that it is concerned about the long-term cardiovascular safety profile of the obesity candidate and has asked Orexigen to conduct an additional study. The request to conduct an additional study means further bad news for Orexigen as this will push up its research and development expenses. Orexigen intends to meet the FDA to discuss the issues raised in the CRL. The decision ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/02/03/orex-orexigen-therapeutics-gets-severe-setback-from-us-food-and-drug-administration/66226/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VVUS) Vivus Seeks EU Nod for Qnexa</title>
		<link>http://www.stockbloghub.com/2010/12/27/vvus-vivus-seeks-eu-nod-for-qnexa/63722</link>
		<comments>http://www.stockbloghub.com/2010/12/27/vvus-vivus-seeks-eu-nod-for-qnexa/63722#comments</comments>
		<pubDate>Tue, 28 Dec 2010 06:46:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Arena Pharmaceuticals Inc.]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[Orexigen Therapeutics Inc.]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=63722</guid>
		<description><![CDATA[Vivus, Inc. (VVUS) recently announced that it has filed a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) seeking approval for Qnexa. The company is looking to get Qnexa approved in the EU for the treatment of obesity (in conjunction with a mildly hypocaloric diet), including weight loss and maintenance of weight loss. Qnexa’s approval would be a major positive for Vivus. The obesity market represents huge commercial potential for Vivus. Obesity is a worldwide epidemic and is estimated to affect about 150 million adults in the EU. A smooth review process could result in Qnexa receiving EU approval in late 2011. Currently available treatments for obesity include orlistat, sold by Roche (RHHBY) as Xenical and by GlaxoSmithKline (GSK) as Alli (available over-the-counter). A commercially available prescription product ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/27/vvus-vivus-seeks-eu-nod-for-qnexa/63722/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca Suffers Pipeline Setback for Motavizumab</title>
		<link>http://www.stockbloghub.com/2010/12/22/azn-astrazeneca-suffers-pipeline-setback-for-motavizumab/63405</link>
		<comments>http://www.stockbloghub.com/2010/12/22/azn-astrazeneca-suffers-pipeline-setback-for-motavizumab/63405#comments</comments>
		<pubDate>Wed, 22 Dec 2010 21:07:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=63405</guid>
		<description><![CDATA[AstraZeneca (AZN) suffered another pipeline setback recently with the company announcing that it no longer intends to develop motavizumab for the prophylaxis of serious respiratory syncytial virus (RSV) disease. The company has requested the US Food and Drug Administration (FDA) to withdraw the Biological License Application (BLA) for the candidate. AstraZeneca expects to incur an impairment charge of $445 million in the fourth quarter of 2010 due to the discontinuation of the development of the candidate. The impairment charge, however, is not expected to impact the company’s core earnings. Rough Regulatory Path for Motavizumab AstraZeneca’s decision does not come as a major surprise as the regulatory process for motavizumab has been rocky. Earlier this year, the FDA’s Antiviral Drugs Advisory Committee had voted against the approval of motavizumab for the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/22/azn-astrazeneca-suffers-pipeline-setback-for-motavizumab/63405/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CRL) Charles River Laboratories Discusses 2011 Outlook</title>
		<link>http://www.stockbloghub.com/2010/12/19/crl-charles-river-laboratories-discusses-2011-outlook/62751</link>
		<comments>http://www.stockbloghub.com/2010/12/19/crl-charles-river-laboratories-discusses-2011-outlook/62751#comments</comments>
		<pubDate>Sun, 19 Dec 2010 23:14:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[MetroPCS Communications Inc.]]></category>
		<category><![CDATA[PCS]]></category>
		<category><![CDATA[RMS]]></category>
		<category><![CDATA[Rydex Inverse 2x S&P MidCap 400]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=62751</guid>
		<description><![CDATA[Charles River Laboratories (CRL) recently discussed its business outlook with investors and clarified its focus on four key initiatives to drive shareholder value. The company also announced 2011 guidance and made some changes to its 2010 outlook. The four key initiatives are as follows: Improving operating margins: The company aims to generate adjusted operating margin of 20% within three-to-five years, which will be driven by cost control and operating efficiencies. The company pegs the Research Models and Services (RMS) segment margins at or slightly above 30% and Pre Clinical Services (PCS) margins in the high teens. The expected improvement in PCS, however, depends on the extent of recovery in the business that has been affected by low demand from pharmaceutical and biotechnology clients. The company has already taken steps to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/19/crl-charles-river-laboratories-discusses-2011-outlook/62751/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca Suffers FDA Regulatory Setback</title>
		<link>http://www.stockbloghub.com/2010/12/18/azn-astrazeneca-suffers-fda-regulatory-setback/62756</link>
		<comments>http://www.stockbloghub.com/2010/12/18/azn-astrazeneca-suffers-fda-regulatory-setback/62756#comments</comments>
		<pubDate>Sat, 18 Dec 2010 20:54:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=62756</guid>
		<description><![CDATA[AstraZeneca (AZN) recently suffered a major setback with the US Food and Drug Administration (FDA) issuing a complete response letter (CRL) for Brilinta (ticagrelor). The company was seeking approval for the use of Brilinta in the treatment of acute coronary syndrome (ACS). The agency has asked AstraZeneca to conduct additional analyses of data from the Study of Platelet Inhibition and Patient Outcomes (PLATO). The PLATO trial was conducted to determine whether Brilinta was more effective in improving cardiovascular outcomes in ACS patients compared to Bristol-Myers Squibb Co./Sanofi-Aventis’ (BMY/SNY) Plavix (clopidogrel). Importantly, AstraZeneca has not been asked to conduct additional studies which could have delayed the approval process even further. The additional delay in Brilinta’s approval is a big disappointment for AstraZeneca which has been banking on Brilinta&#8217;s approval to help ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/18/azn-astrazeneca-suffers-fda-regulatory-setback/62756/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Industry Outlook &#8211; November 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687</link>
		<comments>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687#comments</comments>
		<pubDate>Mon, 15 Nov 2010 18:56:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=58687</guid>
		<description><![CDATA[With 2010 coming to an end, the pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. In fact, 2011 itself will see products worth more than $30 billion losing patent protection. This includes products like Lipitor, Plavix, Zyprexa and Levaquin. According to IMS Health, these products generated more than $17 billion ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JCP) Activist Investors: Follow the Smart Money And Grab an Extra 21% Per Year</title>
		<link>http://www.stockbloghub.com/2010/11/02/jcp-activist-investors-follow-the-smart-money-and-grab-an-extra-21-per-year/55955</link>
		<comments>http://www.stockbloghub.com/2010/11/02/jcp-activist-investors-follow-the-smart-money-and-grab-an-extra-21-per-year/55955#comments</comments>
		<pubDate>Wed, 03 Nov 2010 06:31:38 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Department Stores]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[FO]]></category>
		<category><![CDATA[Fortune Brands Inc.]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[J. C. Penney Company]]></category>
		<category><![CDATA[JCP]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MCD]]></category>
		<category><![CDATA[McDonald's Corporation]]></category>
		<category><![CDATA[SGU]]></category>
		<category><![CDATA[Star Gas Partners LP]]></category>
		<category><![CDATA[Target Corporation]]></category>
		<category><![CDATA[TGT]]></category>
		<category><![CDATA[THI]]></category>
		<category><![CDATA[Tim Hortons Inc.]]></category>
		<category><![CDATA[WEN]]></category>
		<category><![CDATA[Wendy's-Arby's Group Inc]]></category>
		<category><![CDATA[WuXi PharmaTech (Cayman) Inc]]></category>
		<category><![CDATA[WX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=55955</guid>
		<description><![CDATA[by Marc Lichtenfeld, Investment U’s Senior Analyst Wednesday, October 20, 2010: Issue #1370 Every year, a tiny group of investors quietly outperform the stock market by more than 20 percentage points. They’re tough, direct, no-nonsense guys – and are arguably the best people to have fighting for everyday investors like you and me. They’re called activist investors. So who are these guys? What do they do? And more importantly, what can they do for you? “Activists” by Name… And by Nature An activist investor is someone who owns a stake of 5% or more in a certain company and wants to make changes. They’re required to file a 13D document with the SEC, outlining the demands they’re making from management. Those demands often include… The sale of the company or ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/02/jcp-activist-investors-follow-the-smart-money-and-grab-an-extra-21-per-year/55955/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GS) How to Unlock Gains From Corporate America</title>
		<link>http://www.stockbloghub.com/2010/10/27/gs-how-to-unlock-gains-from-corporate-america/56811</link>
		<comments>http://www.stockbloghub.com/2010/10/27/gs-how-to-unlock-gains-from-corporate-america/56811#comments</comments>
		<pubDate>Wed, 27 Oct 2010 20:46:19 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Diversified Investments]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[CYPB]]></category>
		<category><![CDATA[Cypress Bioscience Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[EXTR]]></category>
		<category><![CDATA[Extreme Networks Inc.]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[WuXi PharmaTech (Cayman) Inc]]></category>
		<category><![CDATA[WX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=56811</guid>
		<description><![CDATA[by Marc Lichtenfeld, Investment U’s Senior Analyst Wednesday, October 27, 2010: Issue #1375 Corporate America has a problem. It has too much cash. Hang on… having too much cash isn’t bad, right? On the contrary, in fact. It seems like a nice problem to have. But shareholders of companies that have massive wads of cash have a point in arguing that the executives should put the money to better use, rather than it earning next to nothing in the bank or in low-yielding investments. Typically, investors want that money put towards growing the business instead, usually via acquisitions or by returning it to the shareholders. But American companies aren’t listening. There is, however, a solution for everyday investors – and a company that could be primed to hand out a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/27/gs-how-to-unlock-gains-from-corporate-america/56811/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CVD) Big Pharmaceutical Companies Outsourcing Research and Development</title>
		<link>http://www.stockbloghub.com/2010/10/17/cvd-big-pharmaceutical-companies-outsourcing-research-and-development/55233</link>
		<comments>http://www.stockbloghub.com/2010/10/17/cvd-big-pharmaceutical-companies-outsourcing-research-and-development/55233#comments</comments>
		<pubDate>Mon, 18 Oct 2010 03:42:59 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[Covance Inc.]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[CVD]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ICLR]]></category>
		<category><![CDATA[ICON plc]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Pharmaceutical Product Development Inc]]></category>
		<category><![CDATA[PPDI]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WuXi PharmaTech (Cayman) Inc]]></category>
		<category><![CDATA[WX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=55233</guid>
		<description><![CDATA[by Tony D’Altorio, Investment U Research Thursday, October 14, 2010 Big pharmaceutical companies seem to be taking tips from an unlikely source these days. A decade ago, big mining companies had a big problem on their hands in the form of declining prices. With less incoming funds to spend on finding new deposits, they started thinking creatively… They let small entrepreneurial companies handle early-stage exploration, a difficult task in remote parts of the world. Then, if those operations struck it rich, the big miners swooped in to buy them out. Drug development might not seem like it has much in common with such ventures. But it involves the same high-risk, high reward discovery efforts. So the pharmaceuticals are going for the gold as well with this new approach. Cutting back ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/17/cvd-big-pharmaceutical-companies-outsourcing-research-and-development/55233/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics Announces Challenge to US Food and Drug Administration Decision</title>
		<link>http://www.stockbloghub.com/2010/09/14/ctic-cell-therapeutics-announces-challenge-to-us-food-and-drug-administration-decision/51535</link>
		<comments>http://www.stockbloghub.com/2010/09/14/ctic-cell-therapeutics-announces-challenge-to-us-food-and-drug-administration-decision/51535#comments</comments>
		<pubDate>Wed, 15 Sep 2010 04:02:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[CTIC]]></category>
		<category><![CDATA[PharmAthene Inc]]></category>
		<category><![CDATA[PIP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=51535</guid>
		<description><![CDATA[Recently, Cell Therapeutics Inc. (CTIC) announced that it will appeal against the decision of the US Food and Drug Administration (FDA) to deny approval to the company’s lead candidate, pixantrone. The candidate is being developed for the treatment of relapsed or refractory aggressive non-Hodgkin&#8217;s lymphoma (NHL) in patients who have not responded to other treatment options. In April 2010, the FDA denied approval to pixantrone, and issued a complete response letter (CRL) based on issues related to the study design. The FDA asked Cell Therapeutics to conduct an additional trial to determine the safety and efficacy of pixantrone. The company intends to file an appeal against the decision under the FDA&#8217;s formal dispute resolution process. The decision was based on the fact that management believes there are no approved or ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/14/ctic-cell-therapeutics-announces-challenge-to-us-food-and-drug-administration-decision/51535/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CRL) Charles River Laboratories International&#8217;s Earnings Miss Expectations &#8211; Curbs Expectations</title>
		<link>http://www.stockbloghub.com/2010/08/06/crl-charles-river-laboratories-internationals-earnings-miss-expectations-curbs-expectations/46853</link>
		<comments>http://www.stockbloghub.com/2010/08/06/crl-charles-river-laboratories-internationals-earnings-miss-expectations-curbs-expectations/46853#comments</comments>
		<pubDate>Fri, 06 Aug 2010 16:55:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=46853</guid>
		<description><![CDATA[Charles River Laboratories International Inc.’s (CRL) second quarter 2010 earnings (excluding special items) of 49 cents per share fell short of the Zacks Consensus Estimate of 54 cents. This was approximately 25.8% below the year-ago earnings (excluding special items) of 66 cents. On a reported basis (including special items), the company earned 22 cents per share in the reported quarter as opposed to 52 cents in the year-ago quarter. The decrease in earnings was attributable to lower sales volume and higher costs related to Charles River’s enterprise resource planning (ERP) initiative. The decline was partially mitigated by the cost cutting initiatives undertaken in 2009 and the first quarter of 2010. Net sales for the reported quarter declined 5.2% to $292.1 million, well short of the Zacks Consensus Revenue Estimate of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/06/crl-charles-river-laboratories-internationals-earnings-miss-expectations-curbs-expectations/46853/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Pharma and Biotech Industry Outlook &#8211; July 2010 &#8211; Analyst Interviews</title>
		<link>http://www.stockbloghub.com/2010/07/26/abt-pharma-and-biotech-industry-outlook-july-2010-analyst-interviews/44204</link>
		<comments>http://www.stockbloghub.com/2010/07/26/abt-pharma-and-biotech-industry-outlook-july-2010-analyst-interviews/44204#comments</comments>
		<pubDate>Mon, 26 Jul 2010 14:58:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[ABII]]></category>
		<category><![CDATA[Abraxis Bioscience Inc]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44204</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to cost-cutting ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/26/abt-pharma-and-biotech-industry-outlook-july-2010-analyst-interviews/44204/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Pharma and Biotech Industry Outlook &#8211; July 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/07/20/abt-pharma-and-biotech-industry-outlook-july-2010-industry-outlook/44146</link>
		<comments>http://www.stockbloghub.com/2010/07/20/abt-pharma-and-biotech-industry-outlook-july-2010-industry-outlook/44146#comments</comments>
		<pubDate>Wed, 21 Jul 2010 03:08:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[ABII]]></category>
		<category><![CDATA[Abraxis Bioscience Inc]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44146</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to cost-cutting ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/20/abt-pharma-and-biotech-industry-outlook-july-2010-industry-outlook/44146/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CRL) Charles River Announces Deal to Buy China’s WuXi</title>
		<link>http://www.stockbloghub.com/2010/05/11/crl-charles-river-announces-deal-to-buy-china%e2%80%99s-wuxi/36729</link>
		<comments>http://www.stockbloghub.com/2010/05/11/crl-charles-river-announces-deal-to-buy-china%e2%80%99s-wuxi/36729#comments</comments>
		<pubDate>Tue, 11 May 2010 21:56:22 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[Covance Inc.]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[CVD]]></category>
		<category><![CDATA[Pharmaceutical Product Development Inc]]></category>
		<category><![CDATA[PPDI]]></category>
		<category><![CDATA[WuXi PharmaTech (Cayman) Inc]]></category>
		<category><![CDATA[WX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=36729</guid>
		<description><![CDATA[If you’re a healthcare stocks junkie, you may have caught the news… U.S. clinical research company Charles River Laboratories International (NYSE: CRL) announced a deal to buy its Chinese rival, WuXi PharmaTech ADR (NYSE: WX). The $1.6 billion cash-and-stock deal includes each WuXi ADR receiving $11.25 in cash and $10 of Charles’ common stock. For all intents and purposes, it seems like a good match. Charles River is one of the world’s largest research groups to develop drugs for large pharmaceutical companies to test in humans. And WuXi is one of the biggest Chinese clinical research organizations. It also makes molecules to synthesize drugs, among other things. According to Dealogic, this proposed deal ranks in the top three foreign takeovers of a Chinese company. And it is the largest outside ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/11/crl-charles-river-announces-deal-to-buy-china%e2%80%99s-wuxi/36729/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DCTH) The Decade of Biotech: Two Hot Biotech Sectors and Eight Ways to Profit</title>
		<link>http://www.stockbloghub.com/2010/04/29/dcth-the-decade-of-biotech-two-hot-biotech-sectors-and-eight-ways-to-profit/35446</link>
		<comments>http://www.stockbloghub.com/2010/04/29/dcth-the-decade-of-biotech-two-hot-biotech-sectors-and-eight-ways-to-profit/35446#comments</comments>
		<pubDate>Thu, 29 Apr 2010 14:13:04 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[Covance Inc.]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[CVD]]></category>
		<category><![CDATA[DCTH]]></category>
		<category><![CDATA[Delcath Systems Inc.]]></category>
		<category><![CDATA[Illumina Inc]]></category>
		<category><![CDATA[ILMN]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[Pharmaceutical Product Development Inc]]></category>
		<category><![CDATA[PPDI]]></category>
		<category><![CDATA[SIAL]]></category>
		<category><![CDATA[Sigma-Aldrich Corporation]]></category>
		<category><![CDATA[WuXi PharmaTech (Cayman) Inc]]></category>
		<category><![CDATA[WX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=35446</guid>
		<description><![CDATA[I expect the 2010s to be the “Decade of Biotech.” In 2020, we’ll look back at the past 10 years in amazement at how many medical advances were achieved. And we’ll likely snicker at some of the prehistoric methods that are currently used, equating them to when doctors used to perform lobotomies on people with mental problems. By 2020, there will be new drugs on the market and technologies developed that weren’t even dreamed about at the turn of the 21st century. New discoveries will extend life, or cure diseases that even the most forward-thinking scientists couldn’t have imagined just a short time ago. And fortunes will be made as a result. The question is: How do you grab your piece of the pie? Blasting Tumors… Bagging Profits If you’re ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/29/dcth-the-decade-of-biotech-two-hot-biotech-sectors-and-eight-ways-to-profit/35446/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CRL) Charles River Laboratories International Reports Short of Consensus</title>
		<link>http://www.stockbloghub.com/2010/04/27/crl-charles-river-laboratories-international-reports-short-of-consensus/35003</link>
		<comments>http://www.stockbloghub.com/2010/04/27/crl-charles-river-laboratories-international-reports-short-of-consensus/35003#comments</comments>
		<pubDate>Tue, 27 Apr 2010 17:49:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[WuXi PharmaTech (Cayman) Inc]]></category>
		<category><![CDATA[WX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=35003</guid>
		<description><![CDATA[Charles River Laboratories International Inc.’s (CRL) first quarter 2010 earnings (excluding special items) of 45 cents per share fell short of the Zacks Consensus Estimate of 47 cents. This was 22.4% below the year-ago earnings (excluding special items) of 58 cents. On a reported basis, the company earned 26 cents per share in the reported quarter as opposed to 38 cents in the year-ago quarter. The decrease in earnings was attributable to lower sales volume and higher costs related to Charles River’s enterprise resource planning (ERP) initiative. The decline was partially offset by cost-savings initiatives undertaken in 2009 and in the first quarter of 2010. Total net sales for the reported quarter came in at $297.4 million as against $301.5 million in the year-ago quarter, down approximately 1.4%. Segment-wise, sales ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/27/crl-charles-river-laboratories-international-reports-short-of-consensus/35003/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Johnson and Johnson Suffers Another Pipeline Setback</title>
		<link>http://www.stockbloghub.com/2009/12/31/jnj-johnson-and-johnson-suffers-another-pipeline-setback/24014</link>
		<comments>http://www.stockbloghub.com/2009/12/31/jnj-johnson-and-johnson-suffers-another-pipeline-setback/24014#comments</comments>
		<pubDate>Thu, 31 Dec 2009 18:24:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24014</guid>
		<description><![CDATA[Johnson and Johnson (JNJ) has received yet another setback related to its pipeline candidate ceftobiprole, a broad-spectrum antibiotic ? aiming the methicillin-resistant Staphylococcus aureus (MRSA) ? for the treatment of complicated skin infections and nosocomial pneumonia. Johnson and Johnson had licensed the drug from Swiss drug company Basilea Pharmaceuticals in 2005. Johnson and Johnson received a complete response letter (CRL) from the US Food and Drug Administration (FDA), delaying the approval process further. According to the FDA, there were many flaws in the trials due to which the company has been asked to conduct new studies to evaluate the drug&#8217;s safety and effectiveness. Johnson and Johnson intends to discuss its future course of action related to ceftobiprole with the FDA shortly. The new drug application (NDA) for ceftobiprole has been ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/31/jnj-johnson-and-johnson-suffers-another-pipeline-setback/24014/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca Sees More Good FDA News</title>
		<link>http://www.stockbloghub.com/2009/12/08/azn-astrazeneca-sees-more-good-fda-news/22203</link>
		<comments>http://www.stockbloghub.com/2009/12/08/azn-astrazeneca-sees-more-good-fda-news/22203#comments</comments>
		<pubDate>Tue, 08 Dec 2009 18:21:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[MDD]]></category>
		<category><![CDATA[SPDR S&P International Mid Cap]]></category>
		<category><![CDATA[Targacept Inc]]></category>
		<category><![CDATA[TRGT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22203</guid>
		<description><![CDATA[Good news for AstraZeneca (AZN) once again! The company received US Food and Drug Administration (FDA) approval for Seroquel XR (quetiapine fumarate) as an add-on treatment to antidepressants in adults with Major Depressive Disorder (MDD). Seroquel XR is an extended-release version of the company’s currently marketed Seroquel, which is approved for the treatment of bipolar disorder and schizophrenia.The approval comes shortly after AstraZeneca’s announcement of a billion dollar deal with Targacept (TRGT) for the development of a depression drug. However, the company received a complete response letter (CRL) from FDA for Seroquel’s approval as a first-line treatment for MDD. The agency has asked the company to undertake a Risk Evaluation and Mitigation Strategy (REMS) for all approved indications of Seroquel. This requires a proper survey of patients to ensure their ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/08/azn-astrazeneca-sees-more-good-fda-news/22203/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) FDA Delays Novartis AG Treatment</title>
		<link>http://www.stockbloghub.com/2009/10/20/nvs-fda-delays-novartis-ag-treatment/18131</link>
		<comments>http://www.stockbloghub.com/2009/10/20/nvs-fda-delays-novartis-ag-treatment/18131#comments</comments>
		<pubDate>Tue, 20 Oct 2009 20:15:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18131</guid>
		<description><![CDATA[Recently, Novartis AG (NVS) announced that it has received a Complete Response Letter (CRL) for QAB149 (indacaterol) ? a bronchodilator for the treatment of adults suffering from chronic obstructive pulmonary disease (COPD) ? from the US Food and Drug Administration (FDA). The US agency has asked for additional information on the proposed dosing of the drug. Novartis had filed for the US approval of the drug in December last year. Last month, the Committee for Medicinal Products for Human Use (CHMP) recommended the approval of QAB149 in the European Union to treat COPD patients as a once-daily therapy with two doses (150 micrograms and 300 micrograms). The positive opinion from the CHMP is a boost to Novartis as it aims to be a strong player in the field of respiratory ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/20/nvs-fda-delays-novartis-ag-treatment/18131/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SEPR) Top Small-Cap Equity Funds &#8211; Mutual Fund Commentary</title>
		<link>http://www.stockbloghub.com/2009/10/16/sepr-top-small-cap-equity-funds-mutual-fund-commentary-2/17731</link>
		<comments>http://www.stockbloghub.com/2009/10/16/sepr-top-small-cap-equity-funds-mutual-fund-commentary-2/17731#comments</comments>
		<pubDate>Sat, 17 Oct 2009 00:04:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Medarex Inc]]></category>
		<category><![CDATA[MEDX]]></category>
		<category><![CDATA[SEPR]]></category>
		<category><![CDATA[Sepracor]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17731</guid>
		<description><![CDATA[Today we are featuring top-performing “Small-Cap&#8221; equity mutual funds, which primarily invest in equity securities of companies that have market capitalizations of less than $2 billion. Investors can find such funds by checking out the entire list of the Zacks #1 Rank Small-Cap Equity Funds. 2 Solid Picks Dean Small Cap Value A (DASCX) seeks long-term capital appreciation and secondarily, dividend income. The fund focuses on high-quality companies that are undervalued for transitory reasons in search of above-average returns. The fund may invest in equity securities of mid or large-cap companies, preferred stocks, or derivative instruments, such as put and call options and futures contracts, and in fixed-income securities Incorporatedluding corporate bonds. Unit holders have to make a minimum initial investment of $1,000 to enter this Zacks#1 Rank (“Strong Buy&#8221;) ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/16/sepr-top-small-cap-equity-funds-mutual-fund-commentary-2/17731/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SPPI) Spectrum Pharmaceuticals is Denied Approval from US Food and Drug Administration</title>
		<link>http://www.stockbloghub.com/2009/10/14/sppi-spectrum-pharmaceuticals-is-denied-approval-from-us-food-and-drug-administration/17577</link>
		<comments>http://www.stockbloghub.com/2009/10/14/sppi-spectrum-pharmaceuticals-is-denied-approval-from-us-food-and-drug-administration/17577#comments</comments>
		<pubDate>Wed, 14 Oct 2009 16:42:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Spectrum Pharmaceuticals]]></category>
		<category><![CDATA[SPPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17577</guid>
		<description><![CDATA[In a major disappointment for Spectrum Pharmaceuticals (SPPI), the US Food and Drug Administration (FDA) last week refused to approve the company’s supplemental New Drug Application (sNDA) for Fusilev (levoleucovorin) in its current form. The company was seeking approval for the treatment of patients with advanced metastatic colorectal cancer. Following the news, the shares plummeted 18% on Friday. Spectrum received a Complete Response Letter (CRL) from the FDA, in which the agency stated that the Fusilev data did not confirm the drug’s non-inferiority to leucovorin. Spectrum Pharmaceuticals plans to request a meeting with the agency to discuss the future course of action. The drug is currently approved by the FDA as a treatment option after high dose of methotrexate therapy in patients with osteosarcoma, a type of bone cancer. Earlier ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/14/sppi-spectrum-pharmaceuticals-is-denied-approval-from-us-food-and-drug-administration/17577/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme Fails to Receive Clolar Drug Approval</title>
		<link>http://www.stockbloghub.com/2009/10/08/genz-genzyme-fails-to-receive-clolar-drug-approval/17195</link>
		<comments>http://www.stockbloghub.com/2009/10/08/genz-genzyme-fails-to-receive-clolar-drug-approval/17195#comments</comments>
		<pubDate>Thu, 08 Oct 2009 19:37:28 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALL]]></category>
		<category><![CDATA[Allstate Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17195</guid>
		<description><![CDATA[Yesterday, Genzyme Corp. (GENZ) failed to receive U.S. Food and Drug Administration (FDA) approval for Clolar in elderly adults with acute myeloid leukemia (AML). Clolar is currently approved for pediatric acute lymphoblasic leukemia (ALL) patients who have relapsed or refractory disease after at least two prior regimens. Genzyme was looking to get Clolar approved for the treatment of previously untreated adults aged 60 or older with AML, who have at least one unfavorable prognostic risk factor. In its Complete Response Letter (CRL), the agency stated that Genzyme will have to conduct a randomized, controlled study to gain approval. The response does not come as a surprise as it is in-line with the recommendation of the agency’s Oncologic Drugs Advisory Committee. In early Sep 2009, the FDA’s Oncologic Drugs Advisory Committee ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/08/genz-genzyme-fails-to-receive-clolar-drug-approval/17195/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SEPR) Top Small-Cap Equity Funds &#8211; Mutual Fund Commentary</title>
		<link>http://www.stockbloghub.com/2009/09/23/sepr-top-small-cap-equity-funds-mutual-fund-commentary/15887</link>
		<comments>http://www.stockbloghub.com/2009/09/23/sepr-top-small-cap-equity-funds-mutual-fund-commentary/15887#comments</comments>
		<pubDate>Wed, 23 Sep 2009 20:09:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Charles River Laboratories International]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Medarex Inc]]></category>
		<category><![CDATA[MEDX]]></category>
		<category><![CDATA[SEPR]]></category>
		<category><![CDATA[Sepracor Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15887</guid>
		<description><![CDATA[Today we are featuring top-performing “Small-Cap&#8221; equity mutual funds, which primarily invest in equity securities of companies that have market capitalizations of less than $2 billion. Investors can find such funds by checking out the entire list of the Zacks #1 Rank Small-Cap Equity Funds. 3 Solid Choices Buffalo Small Cap (BUFSX) seeks long-term growth of capital. The fund targets companies with individual market capitalizations of $2 billion or less at the time of initial purchase. The fund primarily invests in common stocks, preferred stocks, convertible preferred stocks warrants and rights of domestic small-cap companies. As of March 2009, its portfolio turnover was 15%. Kent Gasaway has been lead manager at the fund since its inception in April 1998. Previously, Gasaway spent 10 years with Waddell &#38; Reed Mutual Funds ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/23/sepr-top-small-cap-equity-funds-mutual-fund-commentary/15887/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

